Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Mar 23:5:2050312117700809.
doi: 10.1177/2050312117700809. eCollection 2017.

Outcome of misoprostol and oxytocin in induction of labour

Trishna Acharya  1   2 , Ramesh Devkota  1 , Bimbishar Bhattarai  1 , Radha Acharya  3
Affiliations

Outcome of misoprostol and oxytocin in induction of labour

Trishna Acharya et al. SAGE Open Med. .

Abstract

Background: Induction of labour is the process of initiating the labour by artificial means from 24 weeks of gestation. The main aim of this study is to find out the maternal and foetal outcomes after induction of labour with misoprostol and oxytocin beyond 37 weeks of gestation.

Methods: This was a hospital-based observational study carried out at Paropakar Maternity and Women's Hospital, Nepal. Misoprostol of 25 µg was inserted in posterior fornix of vagina or oxytocin infusion was started from 2.5 units on whom induction was decided. Maternal and foetal/neonatal outcomes were observed. Collected data were analysed using SPSS and MS Excel.

Results: General induction rate was found to be 7.2%. In this study, post-term pregnancy was found to be the most common reason for induction of labour. Analysis of onset of labour led to the finding that mean onset of labour was much rapid in oxytocin (6.6 h) than misoprostol (13.6 h). However, there is similarity in induction-delivery interval in both groups. Overall, the rate of normal delivery and caesarean section was found to be 64.9% and 33.2%, respectively. Similarly, normal delivery within 12 h was seen in 18.4% of the patients given with misoprostol and 43.5% in oxytocin group. Foetal distress was found as the most common reason for caesarean section. The overall occurrence of maternal complication was found to be similar in misoprostol and oxytocin groups, nausea/vomiting being the most common (36.7%) complication followed by fever (24.1%). Besides this, the most common neonatal complication found in overall cases was meconium stained liquor (49.2%).

Conclusion: It was found that misoprostol was used most frequently for induction of labour compared to oxytocin. The onset of labour was found to be rapid in oxytocin than misoprostol. However, the occurrence of side effects was found to be similar in both misoprostol and oxytocin groups.

Keywords: Foetal outcome; induction of labour; maternal outcome; misoprostol; neonatal outcome; oxytocin.

PubMed Disclaimer

Conflict of interest statement

Declaration of conflicting interests: The author(s) declared no potential conflicts of interest with respect to the research, authorship and/or publication of this article.

Figures

Figure 1.
Figure 1.
Method of induction.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. World Health Organization. WHO recommendations for induction of labour, http://apps.who.int/iris/bitstream/10665/44531/1/9789241501156_eng.pdf
    1. Wing DA. Induction of labor. In: Queenan JT, Hobbins JC, Spong CY. (eds) Protocols for high-risk pregnancies. Hoboken, NJ: Wiley-Blackwell, 2010, pp. 140–147.
    1. Hofmeyr GJ, Gülmezoglu AM. Vaginal misoprostol for cervical ripening and induction of labour. Cochrane Database Syst Rev 2003; (1): CD000941. - PubMed
    1. World Health Organization. Preparations WECoSfP – quality assurance of pharmaceuticals: meeting a major public health challenge. 2014, http://apps.who.int/medicinedocs/documents/s21390en/s21390en.pdf
    1. Gülmezoglu AM, Crowther CA, Middleton P, et al. Induction of labour for improving birth outcomes for women at or beyond term. Cochrane Database Syst Rev 2012; (6): CD004945. - PMC - PubMed

LinkOut - more resources